Browsing Tag
Follicular lymphoma
12 posts
Can Epcoritamab plus R2 become the new second-line standard in follicular lymphoma after Genmab’s Phase 3 success?
Genmab’s Epcoritamab plus R2 combo cut FL relapse risk by 79% in Phase 3. Find out why this bispecific therapy may reshape second-line treatment.
FDA authorizes breakthrough Epkinly regimen from AbbVie for relapsed or refractory follicular lymphoma
Discover how AbbVie’s newly approved Epkinly regimen with rituximab and lenalidomide is redefining treatment for relapsed or refractory follicular lymphoma.
Genmab’s epcoritamab therapy delivers promising results for relapsed follicular lymphoma
Relapsed or refractory follicular lymphoma (FL) remains a persistent challenge for patients, particularly those with high-risk features. Genmab…
AbbVie and Genmab’s TEPKINLY approved by EC for advanced lymphoma
AbbVie (NYSE: ABBV) and Genmab (NASDAQ: GMAB) have announced that the European Commission (EC) has granted conditional marketing…
Bristol Myers Squibb CAR T cell therapy Breyanzi shows promising outcomes in clinical trials
Bristol Myers Squibb (NYSE: BMY) has unveiled primary analysis results from the TRANSCEND FL clinical trial at the…
Genentech bags Lunsumio FDA approval for R/R follicular lymphoma
Lunsumio FDA approval : Genentech, a subsidiary of the Roche Group, has secured the approval of the US…
Ipsen to acquire American biopharma company Epizyme for $247m
French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration…
Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn
US pharma giant Pfizer has agreed to acquire Trillium Therapeutics, a publicly listed Canadian clinical stage immuno-oncology company,…
Innovent Biologics begins parsaclisib phase 2 trial in follicular lymphoma
Innovent Biologics has dosed the first patient in a phase 2 trial of parsaclisib (IBI-376), a novel and…
Epizyme gets FDA priority review for TAZVERIK in follicular lymphoma
Epizyme has been granted priority review by the US Food and Drug Administration (FDA) for the use of…